Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,911 result(s) found. Displaying page 136 of 146.
    «« First « Previous 132  133  134  135  136  137  138  139  140  Next» Last»»
    EudraCT Number: 2017-000737-31 Sponsor Protocol Number: OOC-ACM-303 Start Date*: 2017-10-27
    Sponsor Name:Chiasma, Inc.
    Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical c...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) PL (Completed) IT (Completed) BG (Completed) LV (Completed) SI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-000378-38 Sponsor Protocol Number: PB-102-F20 Start Date*: 2016-09-07
    Sponsor Name:Protalix Ltd.
    Full Title: A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidas...
    Medical condition: Fabry disease (α-galactosidase A deficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) CZ (Completed) NO (Completed) BE (Completed) NL (Completed) SI (Completed) IT (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003497-14 Sponsor Protocol Number: BLU-285-1303 Start Date*: 2018-04-23
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) SE (Completed) HU (Completed) DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003783-36 Sponsor Protocol Number: R475-PN-1523 Start Date*: 2016-05-19
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip
    Medical condition: Pain due to osteoarthritis of the knee or hip
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10023476 Knee osteoarthritis LLT
    21.1 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DK (Completed) SE (Completed) DE (Completed) LT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) HU (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003447-19 Sponsor Protocol Number: AP26113-13-301 Start Date*: 2016-06-13
    Sponsor Name:ARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited)
    Full Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer
    Medical condition: ALK positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) NL (Completed) FI (Completed) SE (Completed) NO (Completed) DK (Completed) ES (Completed) CZ (Prematurely Ended) PT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005353-38 Sponsor Protocol Number: 12709A Start Date*: 2016-04-11
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disord...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) FI (Not Authorised) DE (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002749-42 Sponsor Protocol Number: GS-US-205-1850 Start Date*: 2017-09-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution...
    Medical condition: Cystic fibrosis and new onset lower respiratory tract culture positive for Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10068288 Cystic fibrosis pulmonary exacerbation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) FR (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed) GR (Completed) DK (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000098-21 Sponsor Protocol Number: TDE-PH-311 Start Date*: 2012-11-06
    Sponsor Name:United Therapeutics Corporation
    Full Title: An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) AT (Completed) FR (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003244-79 Sponsor Protocol Number: 20603 Start Date*: 2020-02-03
    Sponsor Name:Bayer AG
    Full Title: Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial in...
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10064939 Cardiovascular event prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) NL (Completed) DE (Completed) AT (Completed) ES (Completed) SE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003292-22 Sponsor Protocol Number: CVAY736A2201 Start Date*: 2017-06-06
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of ianalumab doses administered subcutaneously in patients with moderate to s...
    Medical condition: Primary Sjogren’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed) GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed) HU (Completed) BE (Completed) AT (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-003644-40 Sponsor Protocol Number: MK-3475-199 Start Date*: 2016-06-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) IE (Completed) DE (Completed) SE (Completed) ES (Completed) EE (Completed) NL (Completed) PL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002980-33 Sponsor Protocol Number: BGB-3111-302 Start Date*: 2017-02-21
    Sponsor Name:BeiGene Ltd. c/o BeiGene USA Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macr...
    Medical condition: Subjects with Waldenström’s Macroglobulinemia (WM) who require therapy according to the consensus panel criteria from the 7th International Workshop on Waldenström’s Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047801 Waldenstrom's macroglobulinaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Completed) ES (Completed) NL (Completed) PL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004827-29 Sponsor Protocol Number: VX14-661-110 Start Date*: 2015-09-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, ...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) AT (Completed) FR (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004902-82 Sponsor Protocol Number: BO28407 Start Date*: 2014-01-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCL...
    Medical condition: HER2-positive operable primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) CZ (Completed) ES (Temporarily Halted) NO (Completed) BE (Prematurely Ended) SE (Prematurely Ended) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000891-27 Sponsor Protocol Number: CLNP023X2203 Start Date*: 2017-11-21
    Sponsor Name:Novartis Pharma AG
    Full Title: An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients
    Medical condition: Primary IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10029149 Nephropathies HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) CZ (Completed) HU (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003607-22 Sponsor Protocol Number: CCFZ533A2201 Start Date*: 2018-07-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody...
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) NO (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004726-34 Sponsor Protocol Number: SHP620-302 Start Date*: 2017-09-01
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...
    Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-005028-11 Sponsor Protocol Number: I4V-MC-JAIM Start Date*: 2019-10-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) HU (Completed) PL (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) NL (Completed) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004084-12 Sponsor Protocol Number: EFC15392 Start Date*: 2018-07-10
    Sponsor Name:Genzyme Corporation
    Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at risk of Rapidly Prog...
    Medical condition: Congenital, hereditary and neonatal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Completed) GB (GB - no longer in EU/EEA) BE (Prematurely Ended) ES (Prematurely Ended) NL (Completed) PT (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005496-87 Sponsor Protocol Number: 161403 Start Date*: 2015-10-15
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NO (Completed) SK (Completed) GR (Completed) AT (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 132  133  134  135  136  137  138  139  140  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 08:18:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA